BR0111002A - Combinação de secretagogos do hormÈnio do crescimento e antidepressivos - Google Patents
Combinação de secretagogos do hormÈnio do crescimento e antidepressivosInfo
- Publication number
- BR0111002A BR0111002A BR0111002-0A BR0111002A BR0111002A BR 0111002 A BR0111002 A BR 0111002A BR 0111002 A BR0111002 A BR 0111002A BR 0111002 A BR0111002 A BR 0111002A
- Authority
- BR
- Brazil
- Prior art keywords
- antidepressants
- prodrug
- methods
- growth hormone
- kits
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 6
- 229940005513 antidepressants Drugs 0.000 title abstract 6
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 2
- 229960002073 sertraline Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000001925 catabolic effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMBINAçãO DE SECRETAGOGOS DO HORMÈNIO DO CRESCIMENTO E ANTIDEPRESSIVOS". Esta invenção refere-se a combinações que incluem um secretagogo do hormónio de crescimento, uma pró-droga do mesmo ou um sal farmaceuticamente aceitável do referido secretagogo do hormónio de crescimento ou da referida pró-droga e um antidepressivo, uma pró-droga do mesmo ou um sal farmaceuticamente aceitável do referido antidepressivo ou da referida pró-droga e a composições farmacêuticas e kits que incluem estas combinações. Os antidepressivos dentro do escopo desta invenção incluem inibidores de reabsorção de norepinefrina (por exemplo, aminas tricíclicas secundárias e terciárias), inibidores seletivos de reabsorção de sertralina, agentes que são combinações de inibidores de reabsorção de norepinefrina/sertralina, inibidores de monoamina oxidase e antidepressivos atípicos. Esta invenção também refere-se a métodos de aperfeiçoamento da condição física e/ou psicológica de um paciente submetido a um procedimento médico, a métodos de tratamento de debilidade esqueleto-muscular, a métodos de tratamento de insuficiência cardíaca congestiva e a métodos de atenuação da resposta catabólica de proteínas após uma grande operação incluindo a administração de tal combinação. Em particular, esta invenção refere-se a tais composições e kits que aperfeiçoam a função cardíaca, metabolismo, tonicidade muscular e/ou estado mental dos pacientes submetidos a um procedimento médico. As composições e kits desta invenção são também úteis no tratamento de distúrbios do sistema nervoso central de pacientes submetidos a um procedimento médico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20701700P | 2000-05-25 | 2000-05-25 | |
| PCT/IB2001/000815 WO2001089570A2 (en) | 2000-05-25 | 2001-05-10 | Combination of growth hormone secretagogues and antidepressants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0111002A true BR0111002A (pt) | 2003-04-15 |
Family
ID=22768871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0111002-0A BR0111002A (pt) | 2000-05-25 | 2001-05-10 | Combinação de secretagogos do hormÈnio do crescimento e antidepressivos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020002137A1 (pt) |
| EP (1) | EP1284753A2 (pt) |
| JP (1) | JP2003534294A (pt) |
| AR (1) | AR028620A1 (pt) |
| AU (1) | AU2001255013A1 (pt) |
| BR (1) | BR0111002A (pt) |
| CA (1) | CA2408036A1 (pt) |
| DO (1) | DOP2001000154A (pt) |
| EC (1) | ECSP014082A (pt) |
| GT (1) | GT200100089A (pt) |
| MX (1) | MXPA02011554A (pt) |
| PA (1) | PA8517701A1 (pt) |
| PE (1) | PE20011262A1 (pt) |
| SV (1) | SV2001000465A (pt) |
| TN (1) | TNSN01076A1 (pt) |
| UY (1) | UY26731A1 (pt) |
| WO (1) | WO2001089570A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1661898A4 (en) | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| EP2200997B9 (en) | 2007-09-13 | 2016-01-13 | Concert Pharmaceuticals Inc. | Synthesis of deuterated benzodioxoles |
| TW200942549A (en) | 2007-12-17 | 2009-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| MA20150428A1 (fr) | 2012-05-03 | 2015-11-30 | Novartis Ag | Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline |
| AU2021365812A1 (en) | 2020-10-21 | 2023-05-11 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2022266193A1 (en) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| WO1998058947A1 (en) * | 1997-06-25 | 1998-12-30 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
-
2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/es unknown
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/es unknown
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/ja active Pending
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/pt not_active Application Discontinuation
- 2001-05-10 CA CA002408036A patent/CA2408036A1/en not_active Abandoned
- 2001-05-10 EP EP01928149A patent/EP1284753A2/en not_active Withdrawn
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/en not_active Application Discontinuation
- 2001-05-17 GT GT200100089A patent/GT200100089A/es unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/es not_active Application Discontinuation
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/es unknown
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/fr unknown
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/es unknown
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/es unknown
- 2001-05-24 AR ARP010102481A patent/AR028620A1/es not_active Application Discontinuation
- 2001-05-25 UY UY26731A patent/UY26731A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20020002137A1 (en) | 2002-01-03 |
| PA8517701A1 (es) | 2002-12-30 |
| ECSP014082A (es) | 2002-04-23 |
| WO2001089570A2 (en) | 2001-11-29 |
| SV2001000465A (es) | 2001-07-03 |
| AR028620A1 (es) | 2003-05-14 |
| WO2001089570A3 (en) | 2002-06-20 |
| PE20011262A1 (es) | 2001-12-11 |
| GT200100089A (es) | 2002-01-11 |
| TNSN01076A1 (fr) | 2005-11-10 |
| CA2408036A1 (en) | 2001-11-29 |
| JP2003534294A (ja) | 2003-11-18 |
| UY26731A1 (es) | 2001-12-28 |
| MXPA02011554A (es) | 2003-04-25 |
| AU2001255013A1 (en) | 2001-12-03 |
| DOP2001000154A (es) | 2002-05-15 |
| EP1284753A2 (en) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002041883A3 (en) | As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| BR0111002A (pt) | Combinação de secretagogos do hormÈnio do crescimento e antidepressivos | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| HUP0103408A2 (hu) | Dopamin-újrafelvétel inhibitorokat tartalmazó kompozíciók és az inhibitorok alkalmazási eljárásai | |
| BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
| KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| RU2003128642A (ru) | Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона | |
| BR0112661A (pt) | Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica | |
| RU2003133217A (ru) | Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме | |
| Nelson et al. | The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials | |
| UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| AR013240A1 (es) | Composiciones, equipos y metodos para inhibir los deseordenes neurovasculares cerebrales y los dolores de cabeza musculares | |
| Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
| NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
| HUP0302436A2 (hu) | Antidepresszáns gyógyszerek által kiváltott szexuális rendellenességek kezelése apomorfinnal | |
| HUP0202525A2 (hu) | Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
| ATE297732T1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| NO982935D0 (no) | Hyaluronsyre reseptor bindende middel og anvendelse derav | |
| YU26401A (sh) | Oralni koncentrat sertralina | |
| BR0111900A (pt) | Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |